Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand

Vladimir Stepanov, Marie Svedberg, Zhisheng Jia, Raisa Krasikova, Laetitia Lemoine, Nobuyuki Okamura, Shozo Furumoto, Nicholas Mitsios, Jan Mulder, Bengt Långström, Agneta Nordberg, Christer Halldin

研究成果: Article査読

12 被引用数 (Scopus)


Introduction Due to the rise in the number of patients with dementia the imperative for finding new diagnostic and treatment options becomes ever more pressing. While significant progress has been made in PET imaging of Aβ aggregates both in vitro and in vivo, options for imaging tau protein aggregates selectively are still limited. Based on the work previously published by researchers from the Tohoku University, Japan, that resulted in the development of [18F]THK-5351, we have undertaken an effort to develop a carbon-11 version of the identical structure - [11C]THK-5351. In parallel, THK-5351 was also labeled with tritium ([3H]THK-5351) for use in in vitro autoradiography (ARG). Methods The carbon-11 labeling was performed starting with di-protected enantiomeric pure precursor - tert-butyl 5-(6-((2S)-3-fluoro-2-(tetrahydro-2H-pyran-2-yloxy)propoxy)quinolin-2-yl)pyridin-2-yl carbamate, which was reacted with [11C]MeI, using DMF as the solvent and NaH as base, followed by deprotection with trifluoroacetic acid/water mixture, resulting in enantiomerically pure carbon-11 radioligand, [11C]THK-5351 - (S)-1-fluoro-3-(2-(6-([11C]methylamino)pyridin-3-yl)quinolin-6-yloxy)propan-2-ol. Tritium labeling and purification of [3H]THK-5351 were undertaken using similar approach, resulting in [3H]THK-5351 with RCP >99.8% and specific radioactivity of 1.3 GBq/μmol. Results [11C]THK-5351 was produced in good yield (1900 ± 355 MBq), specific radioactivity (SRA) (361 ± 119 GBq/μmol at EOS + 20 min) and radiochemical purity (RCP) (>99.8%), with enantiomeric purity of 98.7%. [3H]THK-5351 was evaluated for ARG of tau binding in post-mortem human brain tissue using cortical sections from one AD patient and one control subject. [3H]THK-5351 binding density was higher in the AD patient compared to the control subject, the binding was displaced by unlabeled THK-5351 confirming specific [3H]THK-5351 binding.

ジャーナルNuclear Medicine and Biology
出版ステータスPublished - 2017 3月 1

ASJC Scopus subject areas

  • 分子医療
  • 放射線学、核医学およびイメージング
  • 癌研究


「Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。